Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.01 USD
-0.20 (-2.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.02 +0.01 (0.12%) 6:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Theravance Biopharma, Inc. [TBPH]
Reports for Purchase
Showing records 21 - 40 ( 217 total )
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
PIFR-2 Study Result was Disappointing, We See Plenty of Runway for Yupelri; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for TBPH 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Yupelri Continues To Chug Along as Theravance Approaches Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
2Q Sales Came Below Expectations But Yupelri?s Growth Indicators Remain Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department